Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML.

Christoph Rummelt, Sivahari P. Gorantla, Michael Sigl, Jana Saenger, Katharina Götze, Christian Peschel, MD, Justus Duyster, Nikolas von Bubnoff

Blood (2012) 120 (21): 2423.

https://doi.org/10.1182/blood.V120.21.2423.2423

Published: 2012

Journal Articles

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Walter Fiedler, MD, Sabine Kayser, Maxim Kebenko, M.D., Jürgen Krauter, MD, PhD, Helmut R. Salih, M.D., Katharina Götze, M.D., Daniela Späth, MSc, Gudrun Göhring, MD, Veronica Teleanu, MD, Konstanze Döhner, MD, Arnold Ganser, Hartmut Döhner, MD, Richard F Schlenk, MD

Blood (2012) 120 (21): 1483.

https://doi.org/10.1182/blood.V120.21.1483.1483

Published: 2012

Journal Articles

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Blood (2012) 120 (21): 785.

https://doi.org/10.1182/blood.V120.21.785.785

Published: 2012

Journal Articles

Chromosomal Aberrations Identified in CD34+ Peripheral Blood Cells of MDS Patients by FISH- and SNP Array Analysis

Christina Ganster, Katayoon Shirneshan, Gabriela Salinas-Riester, Friederike Braulke, Katharina Götze, Uwe Platzbecker, MD, Detlef Haase

Blood (2011) 118 (21): 4872.

https://doi.org/10.1182/blood.V118.21.4872.4872

Published: 2011

Journal Articles

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Blood (2011) 118 (21): 80.

https://doi.org/10.1182/blood.V118.21.80.80

Published: 2011

Journal Articles

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

Uwe Platzbecker, MD, Christina Ganster, Jürgen Neesen, Andrea Kuendgen, MD, Katharina Götze, Gesine Bug, Katayoon Shirneshan, Friederike Braulke, Christoph Röllig, MD, Ralph Naumann, MD, Eckhard Büssemaker, Aristoteles Giagounidis, MD, Wolf-Karsten Hofmann, MD, Ulrich Germing, MD, Detlef Haase, Gerhard Ehninger, MD

Blood (2011) 118 (21): 3799.

https://doi.org/10.1182/blood.V118.21.3799.3799

Published: 2011

Journal Articles

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Blood (2011) 118 (21): 412.

https://doi.org/10.1182/blood.V118.21.412.412

Published: 2011

Journal Articles

Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study

Katayoon Shirneshan, Ulrich Germing, Friederike Braulke, Julie Schanz, Uwe Platzbecker, MD, Aristoteles Giagounidis, Florian Nolte, Katharina Götze, Detlef Haase

Blood (2011) 118 (21): 1721.

https://doi.org/10.1182/blood.V118.21.1721.1721

Published: 2011

Journal Articles

Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study

Michela Tassara, eronika Hofer, V, Konstanze Döhner, Marie Lilienfeld-Toal, Gerhard Held, MD, Katharina Götze, Heinz A. Horst, MD, PhD, Sibylla Wilhelm, MD, Stephan Kremers, CA, MD, Elisabeth Koller, Daniela Späth, Silja Mack, Carina Morlok, Martin Göttlicher, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 185.

https://doi.org/10.1182/blood.V116.21.185.185

Published: 2010

Journal Articles

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

Blood (2010) 116 (21): 3314.

https://doi.org/10.1182/blood.V116.21.3314.3314

Published: 2010

Journal Articles

A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Walter Fiedler, MD, Jürgen Krauter, MD, Katharina Götze, Helmut R. Salih, MD, Carsten Bokemeyer, MD, Daniela Spaeth, Konstanze Döhner, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 3285.

https://doi.org/10.1182/blood.V116.21.3285.3285

Published: 2010

Journal Articles

Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification

Michela Tassara, Konstanze Döhner, Christine Schöpflin, Anke Schmid, Heinz A. Horst, MD, PhD, Gerhard Held, MD, Marie Lilienfeld-Toal, Sibylla Wilhelm, MD, Andrea Kündgen, Katharina Götze, Mathias J. Rummel, MD, PhD, David Nachbaur, MD, Walter Fiedler, MD, Michael Lübbert, MD, Helmut R. Salih, MD, Jörg Westermann, Arnold Ganser, MD, Hartmut Döhner, MD, Richard F. Schlenk, MD

Blood (2010) 116 (21): 1693.

https://doi.org/10.1182/blood.V116.21.1693.1693

Published: 2010

Journal Articles

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Uwe Platzbecker, Detlef Haase, Friederike Braulke, Gesine Bug, Katharina Götze, Andrea Kuendgen, Christoph Röllig, Martin Wermke, Ralph Naumann, Martin Bornhäuser, Aristoteles Giagounidis, Ulrich Germing, Wolf-Karsten Hofmann, Gerhard Ehninger

Blood (2010) 116 (21): 4000.

https://doi.org/10.1182/blood.V116.21.4000.4000

Published: 2010

Journal Articles

Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications

Blood (2010) 116 (21): 909.

https://doi.org/10.1182/blood.V116.21.909.909

Published: 2010

Journal Articles

Combination of c-SRC and FLT3 Inhibitors Has An Additive Inhibitory Effect on FLT3 ITD but Not on FLT3 TKD Positive Cells

Hannes Leischner, Rebekka Grundler, Corinna Albers, Anna Lena Illert, MD, Katharina Götze, MD, Christian Peschel, MD, Justus Duyster, MD

Blood (2010) 116 (21): 2892.

https://doi.org/10.1182/blood.V116.21.2892.2892

Published: 2010

Journal Articles

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

Friederike Braulke, MD, Julie Schanz, MD, Michael Metz, MD, Sven Detken, MD, Joerg Seraphin, MD, Katharina Götze, MD, Catharina Mueller-Thomas, MD, Uwe Platzbecker, MD, Tim Henrik Brümmendorf, MD, Aristoteles A.N. Giagounidis, MD, Ulrich Germing, MD, Kathleen Jentsch-Ullrich, MD, Angelika Boehme, MD, Gesine Bug, MD, Oliver G. Ottmann, Prof, Dr., med., Philippe Schafhausen, MD, Lorenz Trümper, MD, Detlef Haase, MD

Blood (2010) 116 (21): 2937.

https://doi.org/10.1182/blood.V116.21.2937.2937

Published: 2010

Journal Articles

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Blood (2009) 114 (22): 945.

https://doi.org/10.1182/blood.V114.22.945.945

Published: 2009

Journal Articles

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Anne Sonet, Carlos Graux, Johan Maertens, Christine-Maria Hartog, Justus Duyster, Katharina Götze, Jochen Greiner, Marie-Luise Hütter, Alois Gratwohl, Dominik Heim, Dagmar Hess, Yves Chalandon, Athos Gianella-Borradori, Narmyn Rejeb, Oliver Ottmann

Blood (2008) 112 (11): 2963.

https://doi.org/10.1182/blood.V112.11.2963.2963

Published: 2008

Journal Articles

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

Marie-Luise Hütter, Konstanze Döhner, Ingo G.H. Schmidt-Wolf, Francisco Del Valle, Björn Heydrich, Wolfgang Heit, Walter Fiedler, Michael Pfreundschuh, MD, PhD, Gudrun Russ, Martin Bentz, Aruna Raghavachar, Detlef Haase, MD, PhD, Wolfram Brugger, MD, Katharina Götze, Silja Groner, Hartmut Döhner, Richard Schlenk

Blood (2008) 112 (11): 559.

https://doi.org/10.1182/blood.V112.11.559.559

Published: 2008

Journal Articles

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

Blood (2007) 110 (11): 1837.

https://doi.org/10.1182/blood.V110.11.1837.1837

Published: 2007

NARROW

FLT3-ITD Interacts with and Phosphorylates IL-3β, and JAK1/2 Dependent IL-3β Activation Bypasses FLT3-ITD in FLT3 Kinase Independent Inhibitor Resistance in Vitro: Evidence for the Significance of IL-3β for FLT3-ITD Dependent Oncogeneic Signaling in AML.

Sunitinib and Intensive Chemotherapy in Patients with Acute Myeloid Leukemia and Activating FLT3 Mutations: Results of the AMLSG 10-07 Study (ClinicalTrials.gov No. NCT00783653)

Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication

Chromosomal Aberrations Identified in CD34+ Peripheral Blood Cells of MDS Patients by FISH- and SNP Array Analysis

All- Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia – Results of the AMLSG 07-04 Randomized Treatment Trial

Safety and Efficacy of a Combination of 5-Azacitidine Followed by Lenalidomide in High-Risk MDS or AML Patients with Del(5q) Cytogenetic Abnormalities – Results of the “AZALE” Trial,

ASXL1 Mutations Predict for Resistance to Chemotherapy and Inferior Outcome in Younger Adult Patients with Acute Myeloid Leukemia (AML): A Study of the German-Austrian AMLSG

Genetic Response to Lenalidomide in the Circulating Progenitor Cell Compartment of MDS Cohort. Preliminary Results of the Multicenter German LE-MON-5 Study

Prospective Phase III Trial of Valproic acid (VPA) In Combination with All-Trans Retinoic Acid (ATRA) and Intensive Induction Therapy for AML In Older Patients: The German-Austrian AMLSG 06-04 Study

Sorafenib Monotherapy Is Effective In Relapsed and RefractoryFlt3-ITD Positive Acute Myeloid Leukemia, Particularly After Allogenic Stem Cell Transplantation

A Phase I/II Study Combining Sunitinib with Standard Ara-C/Daunorubicin Chemotherapy In Patients 60 Years or Older with FLT3 Mutated AML

Prospective Evaluation of Immunophenotype In Correlation to Genotype In Previously Untreated Adult Patients with Acute Myeloid Leukemia In the Context of the WHO Classification

A Phase I Study of a Combination of 5-Azacyitidine Followed by Lenalidomide In High-Risk MDS or AML Patients with Chromosome 5 Abnormalities – Interim Results of the “AZALE” Trial

Impact of Allogeneic Transplantation From Matched Related and Unrelated Donors on Clinical Outcome In Younger Adult AML Patients with FLT3 Internal Tandem Duplications

Combination of c-SRC and FLT3 Inhibitors Has An Additive Inhibitory Effect on FLT3 ITD but Not on FLT3 TKD Positive Cells

Detection of Karyotype Evolution From Peripheral Blood by Sequential FISH Analyses of Circulating CD34+ Cells In MDS Patients: Results of the Ongoing German Multicenter Prospective Diagnostic Study

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Phase I, Dose-Escalation Study of 2 Dosing Regimens of AS703569, An Inhibitor of Aurora and Other Kinases, Administered Orally in Patients with Advanced Hematological Malignancies

Role of Etoposide in Combination with All- Trans Retinoic Acid in the Treatment of Elderly Patients with Acute Myeloid Leukemia and NPM1 Mutation

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of AMLSG 05-04 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only